Entecavir versus other oral antiviral drugs for chronic hepatitis B
نویسندگان
چکیده
منابع مشابه
Adverse effects of oral antiviral therapy in chronic hepatitis B
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class...
متن کاملentecavir versus lamivudine therapy for patients with chronic hepatitis b-associated liver failure: a meta-analysis
conclusions etv and lam treatments had similar effects to improve 24 weeks survival rate of patients with chb-associated liver failure, but etv was associated with greater clinical improvement. both drugs were tolerated well during the treatment. it is suggested to perform further studies to verify the results. background nucleoside analogues are recommended as antiviral treatments for patients...
متن کاملA five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients
Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients. To investigate the efficacy of ETV in Chinese nucleos(t)ide(NA)-experienced CHB patients. Among 89 CHB patients with ETV monotherapy for ≥6 months, 33/89 (37%) or 56/89 (73%) were NA-naïve or NA-experienced. During a median follow-up of 5.75 years, all NA-naïve CHB patients achieved VR without genoty...
متن کاملAntiviral therapy for chronic hepatitis B.
The goal of antiviral therapy for chronic hepatitis B is to prevent the development of cirrhosis and hepatocellular carcinoma. End points, including viral suppression, alanine aminotransferase normalization, hepatitis B e antigen loss, hepatitis B surface antigen loss, and improvement in liver histology, are used to determine treatment success. Treatment is based on hepatitis B virus (HBV) repl...
متن کاملCurrent Antiviral Therapy for Chronic Hepatitis B
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil. In patients with HBeAgpositive chronic hepatitis B, all of these drugs achieve HBeAg loss (24-33%) and anti-HBe seroconversion (12-30%) rates that are superior to those o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2018
ISSN: 1465-1858
DOI: 10.1002/14651858.cd013081